USANA Health Sciences, Inc. (NYSE:USNA) has received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $73.67.
USNA has been the subject of several recent analyst reports. Zacks Investment Research raised shares of USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $86.00 price objective for the company in a research note on Saturday, October 26th. ValuEngine raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Jefferies Financial Group initiated coverage on USANA Health Sciences in a report on Thursday, August 22nd. They set a “hold” rating and a $65.00 price target on the stock.
In other news, insider Joshua Foukas sold 1,115 shares of USANA Health Sciences stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $74.53, for a total value of $83,100.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Auciaux sold 4,018 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $71.87, for a total transaction of $288,773.66. The disclosure for this sale can be found here. Insiders have sold 8,385 shares of company stock worth $617,279 in the last three months. 42.50% of the stock is currently owned by insiders.
USNA stock opened at $73.67 on Friday. The firm has a market cap of $1.59 billion, a P/E ratio of 14.28 and a beta of 0.30. The firm’s fifty day moving average is $73.12 and its 200 day moving average is $70.34. USANA Health Sciences has a 52 week low of $58.30 and a 52 week high of $125.61.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.22. USANA Health Sciences had a net margin of 9.38% and a return on equity of 27.60%. The business had revenue of $260.60 million during the quarter, compared to analyst estimates of $256.22 million. During the same period in the prior year, the business posted $1.24 earnings per share. The company’s revenue was down 12.2% on a year-over-year basis. As a group, equities analysts predict that USANA Health Sciences will post 3.99 earnings per share for the current fiscal year.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Featured Article: Trading Strategy
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.